Form 4: Denali Therapeutics Director Vicki L. Sato Reports Stock Sale
SEC Form 4 Filing
Director Vicki L. Sato of Denali Therapeutics Inc. reports selling 3,080 shares of common stock at an average price of $27.07.
Summary
- On November 1, 2024, Vicki L. Sato, a director of Denali Therapeutics Inc., sold 3,080 shares of common stock.
- The shares were sold at a weighted average price of $27.07, with individual prices ranging from $26.60 to $27.41 per share.
- The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 21, 2024.
- Following the transaction, Sato directly owns 112,076 shares of Denali Therapeutics Inc., which includes 5,967 unvested Restricted Stock Units (RSUs).
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing simply reports a stock sale under a pre-arranged trading plan, with no explicit indication of positive or negative sentiment towards the company's prospects.
Industry Context
This filing is a routine disclosure of insider trading activity. It provides transparency into the transactions of company insiders, allowing investors to monitor potential alignment or misalignment of interests between management and shareholders.
Stakeholder Impact
- The stock sale by a director could be perceived negatively by some shareholders, but the existence of a pre-arranged trading plan mitigates this concern.
Key Dates
| Date | Description |
|---|---|
| 2024-03-21 | Date of adoption of Rule 10b5-1 trading plan |
| 2024-11-01 | Date of stock sale transaction |
| 2024-11-05 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.